Friday, 14 Jun 2019

You are here

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.

Gout patients with a gout flare in the last 12 months were randomly assigned to receive either specially trained, nurse-led care or continue with GP-led usual care. The primary endpoint was the percentage of participants who achieved serum urate concentrations less than 360 μmol/L (6 mg/dL) at 2 years.

A total of 517 gout patients were enrolled, of whom 255 were assigned nurse-led care and 262 usual care. The results were staggeringly in favor of nurse-led care, especially with regard to:

  • Uptake of and adherence to urate-lowering therapy (96% vs 56%, p = 0·0053 )
  • Achieving target urate at 2 years (95% vs 30%, RR 3·18, 95% CI 2·42–4·18, p<0·0001).
  • Fewer flares after 2 years (8% vs 24%;  p <0·0001)
  • The cost per QALY gained for the nurse-led intervention was £5066 at 2 years.

Community-based nurse-led care involving education and engagement of patients and a treat-to-target strategy for urate-lowering therapy achieved target serum urate concentrations and improved patient-centred outcomes in more than 90% of patients with gout.   This study underscores the benefits of educating and engaging patients in gout management and reaffirm the importance of a treat-to-target urate-lowering treatment strategy to improve patient-centred outcomes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

Despite Gout Numbers and Flares, Allopurinol is Underutilized

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.